scm logo

On April 29, the R&D department under the Research & Business Innovative Development Division of SCM Lifescience, Inc. participated in

the “2022 Korean Society for Tissue Engineering × Regenerative Medicine Society (KTERMS) Emerging Researchers Symposium” held at CHA Bio Complex, CHA University.

This symposium is KTERMS's first academic activity of the year, consisting of eight sessions in each field,

and was conducted with a lecture introducing the latest research results and technologies of emerging academic researchers who have recently achieved a lot of excellent results.

Until now, tissue engineering biomaterials for human transplantation and advanced techniques have been continuously developed.

However, since it is very difficult to bind cells suitable for the target disease, the reality is that there is no treatment with a clear effect in regenerative medicine.

In this symposium, many emerging researchers emphasized the need for cell-based fusion research.

Accordingly, the R&D department, which is exploring new indications, was a good opportunity to understand the current status and trends of research that confirms efficacy by introducing mesenchymal stem cells and cells essential for target diseases into tissue-engineered materials.

In addition, field meetings were held with several participating researchers through the symposium, it was a good opportunity to introduce SCM Lifescience, Inc.’s high-purity and high-efficiency stem cells and to confirm the high demand for our stem cells once again.

In the second half of the symposium, So-Ra Park, chairman of the Regenerative Medicine Promotion Foundation, and Yun-Hyeok Choi, director of the Pan-ministerial Regenerative Medical Technology Development Project, explained the direction of advanced research and the direction of the technology development project. Through this, he emphasized that the ultimate success is to secure global source technology and rights, clinical pipeline operation know-how, and production infrastructure. 

SCM Lifescience Inc. once again learned about the high demand for high-purity and high-efficiency stem cells through this symposium and evaluated it as a symposium that helped a lot in planning the next research field and clinical pipeline.